



August 12, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

On July 17, 2019, and pursuant to 18 V.S.A. § 4637(b), Teva Pharmaceuticals USA, Inc. (“Teva”) submitted a new drug introduction notice for the following (collectively, the “Product”):

NDC	Product Description	WAC
00093-3066-34	ICATIBANT ACETATE 10MG/ML PFS SOL 3ML 1	\$5,083.26
00093-3066-93	ICATIBANT ACETATE 10MG/ML PFS SOL 3ML 3	\$15,249.78

Teva now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

- 1. US and international marketing and pricing plans used at launch:** Teva declines to provide this information in accordance with 18 V.S.A. § 4637(d).
- 2. Estimated volume of patients:** Average of approximately 720 total prescriptions per month (both pack sizes), based on IQVIA data.
- 3. Whether the FDA granted breakthrough therapy designation or priority review:** Neither.
- 4. Date and price of acquisition:** Not applicable; Teva developed the Product.

\* \* \* \*

Teva provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this report, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Thank you for your consideration.

Sincerely,

Brian Savage  
General Counsel, US Generics  
Teva Pharmaceuticals USA, Inc.